ACAD Stock Recent News

Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to Nuplazid Phase 3 trial failure for schizophrenia. Despite setbacks, Acadia has strong financials with $470.5 million in cash and investments, and is trading at two times FY24 revenue net of cash. An updated analysis around Acadia Pharmaceuticals follows in the paragraphs below.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting, being held this week in Westminster, Colorado. LOTUS is an ongoing, caregiver-reported study evaluating the efficacy and tolerability outcomes in patients with Rett syndrome treated with DAYBUE™ (trofinetide). “These interim data from the LOTUS s.

BERKELEY, Calif.--(BUSINESS WIRE)--Millie, a modern maternity clinic, today revealed promising maternal health outcomes from the first cohort of more than 150 births from its hybrid model that combines midwifery-led care, doulas, and OB-GYN support with technology to provide more complete, proactive, and right-sized care. Millie's 360-degree approach has shown the potential to improve key outcomes while also demonstrating a model for addressing national OB-GYN shortages. Health Outcomes In comp.

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

ACADIA Pharmaceuticals is a biopharmaceutical company specializing in CNS disorder treatments, with two successful FDA-approved commercial products, Nuplazid and Daybue. Nuplazid, indicated for Parkinson's disease psychosis, generates over $300 million in yearly cash flow, while Daybue, approved for Rett syndrome, had a successful launch. ACAD has a promising pipeline of drug candidates, including ACP-101 for Prader-Willi syndrome and ACP-204 for Alzheimer's disease psychosis, which could create additional revenue verticals.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on May 15, 2024, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 57,252 shares of common stock and 33,675 restricted stock units (“RSUs”) to twenty-two new employees under Acadia's 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' e.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Citizens JMP Life Sciences Conference Fireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY 2024 RBC Capital Markets Global Healthcare Conference Fireside Chat: Wednesday, May 15, 2024 at 11:30 a.m. Eastern Time in New York, NY BofA Securities Health Care Conference Fireside Chat: Wednesday, May 16, 2024 at 12:20 p.m. Ea.

Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Corporate Participants Al Kildani - Senior Vice President, Investor Relations and Corporate Communications Steve Davis - President and Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Kimberly Manhard - Senior Vice President, Global Strategic Planning and Execution Mark Schneyer - Chief Financial Officer Conference Call Participants Tessa Romero - JPMorgan Ritu Baral - TD Cowen Gregory Renza - RBC Capital Markets Ami Fadia - Needham & Company Yatin Suneja - Guggenheim David Hoang - Citigroup Joel Beatty - Baird Elaine Kim - Cantor Jose Lora - Citizens JMP Ash Verma - UBS Marc Goodman - Leerink Sumanth Kulkarni - Canaccord Genuity Uy Ear - Mizuho Operator Good day, everyone, and thank you for standing by. Welcome to the ACADIA Pharmaceuticals First Quarter 2024 Financial Results and Operating Overview Conference Call.

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to loss of $0.27 per share a year ago.